The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

IAPAC Monthly
Table of Contents, January 2003

IAPAC Monthly magazine


Report From the President
Routing Out Indifference
By José M. Zuniga

In the News
IAPAC Commits to "Fast Action" in Face of Global Challenges
By Scott A. Wolfe

Time to Move on HIV/AIDS Treatment and Care
By Bernhard Schwartländer and Joep M.A. Lange


In the Life
Claire Touchie

Say Anything

Heavy Lifting in Glasgow (Wherein HIV Researchers Uncrate Some Clydeside Surprises)
After a year of meetings rife with HIV treatment news, how much can you expect from the Glasgow congress? Plenty. Pharmacokinetic curiosities included d4T triphosphate in people taking AZT, and indinavir/ritonavir lite -- 400/100 mg twice a day. A clutch of clinic reports agreed that long responders are replacing nonresponders, while other studies showed how T-cell counts sway STI results. New drugs on the agenda included T-20, atazanavir, and amprenavir's prodrug.
By Mark Mascolini

Editor-in-Chief: José M. Zuniga

Managing Editor: Lisa McKamy

Political Editor: Scott A. Wolfe

Creative/Design Director: Holly J. Emanuelson

Advertising Director: Michael S. Glass

Writer-at-Large: Mark Mascolini

Contributing Writers: Lisa Keen, Dave MacDougall

IAPAC Monthly
33 N. LaSalle, Suite 1700
Chicago, IL 60602-2601, USA
Fax: (212) 367-1528
©2003 IAPAC Monthly

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by International Association of Physicians in AIDS Care. It is a part of the publication IAPAC Monthly.